Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

References

• Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol 2008;115:9–24.
   PubMed Web of Science ®Google Scholar
• Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev 2013;6:3–16.
   PubMedGoogle Scholar
• Vastag B. Addiction research. Ibogaine therapy: a ‘vast, uncontrolled experiment’. Science 2005;308:345–346.
   PubMed Web of Science ®Google Scholar
• Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict 1999;8:234–242.
   PubMed Web of Science ®Google Scholar
• Mash DC, Kovera CA, Pablo J, Tyndale R, Ervin FR, Kamlet JD, Hearn WL. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol 2001;56:155–171.
   PubMedGoogle Scholar
• Alper KR. Ibogaine: a review. Alkaloids Chem Biol 2001;56:1–38.
   PubMedGoogle Scholar
• Bastiaans E. Life after ibogaine: an exploratory study of the long-term effects of ibogaine treatment on drug addicts. Doctorandus thesis. Faculty of Medicine Vrije Universiteit Amsterdam 2004. URL https://www.iceers.org/docs/science/iboga/Bastiaans%20E_Life_After_Ibogaine.pdf (accessed April 11, 2017).
   Google Scholar
• Schenberg EE, De Castro Comis MA, Chaves BR, Da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol 2014;28:993–1000.
   PubMed Web of Science ®Google Scholar
• Cloutier-Gill L, Wood E, Millar T, Ferris C, Eugenia Socias M. Remission of severe opioid Use disorder with ibogaine: a case report. J Psychoactive Drugs 2016;48:214–217.
   PubMed Web of Science ®Google Scholar
• Sisko B. Interrupting drug dependency with ibogaine: a summary of four case histories. Multidisciplinary Assoc Psychedelic Stud (MAPS) Newslett 1993;4:15–24.
   Google Scholar
• Lotsof HS, Alexander NE. Case studies of ibogaine treatment: implications for patient management strategies. Alkaloids Chem Biol 2001;56:293–313.
   PubMedGoogle Scholar
• Dzoljic ED, Kaplan CD, Dzoljic MR. Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats. Arch Int Pharmacodyn Ther 1988;294:64–70.
   PubMedGoogle Scholar
• Cappendijk SL, Fekkes D, Dzoljic MR. The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine. Behav Brain Res 1994;65:117–119.
   PubMed Web of Science ®Google Scholar
• Glick SD, Rossman K, Rao NC, Maisonneuve IM, Carlson JN. Effects of ibogaine on acute signs of morphine-withdrawal in rats - independence from tremor. Neuropharmacology 1992;31:497–500.
   PubMed Web of Science ®Google Scholar
• Parker LA, Burton P, McDonald RV, Kim JA, Siegel S. Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:293–297.
   PubMed Web of Science ®Google Scholar
• Frances B, Gout R, Cros J, Zajac JM. Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice. Fundam Clin Pharmacol 1992;6:327–332.
   PubMed Web of Science ®Google Scholar
• Layer RT, Skolnick P, Bertha CM, Bandarage UK, Kuehne ME, Popik P. Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors. Eur J Pharmacol 1996;309:159–165.
   PubMed Web of Science ®Google Scholar
• Leal MB, Michelin K, Souza DO, Elisabetsky E. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:781–785.
   PubMed Web of Science ®Google Scholar
• Popik P, Layer RT, Fossom LH, Benveniste M, Geterdouglass B, Witkin JM, Skolnick P. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J Pharmacol Exp Ther 1995;275:753–760.
   PubMed Web of Science ®Google Scholar
• Aceto MD, Bowman ER, Harris LS, May EL. Dependence studies of new compounds in the rhesus monkey and mouse (1991). NIDA Res Monogr 1992;119:513–558.
   PubMedGoogle Scholar
• Koja T, Fukuzaki K, Kamenosono T, Nishimura A, Nagata R, Lukas SE. Inhibition of opioid abstinent phenomena by Ibogaine. 69th annual meeting of the Japanese Pharmacological Society, March 20–23, 1996. Jpn J Pharmacol 1996;71:89.
   PubMedGoogle Scholar
• Belgers M, Leenaars M, Homberg JR, Ritskes-Hoitinga M, Schellekens AF, Hooijmans CR. Ibogaine and addiction in the animal model, a systematic review and meta-analysis. Transl Psychiatry 2016;6:e826.
   PubMed Web of Science ®Google Scholar
• Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN. Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur J Pharmacol 1991;195:341–345.
   PubMed Web of Science ®Google Scholar
• Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW Jr., Carlson JN. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res 1994;657:14–22.
   PubMed Web of Science ®Google Scholar
• Glick SD, Pearl SM, Cai J, Maisonneuve IM. Ibogaine-like effects of noribogaine in rats. Brain Res 1996;713:294–297.
   PubMed Web of Science ®Google Scholar
• Dworkin SI, Gleeson S, Meloni D, Koves TR, Martin TJ. Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats. Psychopharmacology (Berl) 1995;117:257–261.
   PubMed Web of Science ®Google Scholar
• Maisonneuve IM, Glick SD. Interactions between ibogaine and cocaine in rats - invivo microdialysis and motor behavior. Eur J Pharmacol 1992;212:263–266.
   PubMed Web of Science ®Google Scholar
• Cappendijk SL, Dzoljic MR. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J Pharmacol 1993;241:261–265.
   PubMed Web of Science ®Google Scholar
• Sershen H, Hashim A, Lajtha A. Ibogaine reduces preference for cocaine consumption in C57BL/6By mice. Pharmacol Biochem Behav 1994;47:13–19.
   PubMed Web of Science ®Google Scholar
• Maisonneuve IM, Keller RW Jr., Glick SD. Interactions of ibogaine and D-amphetamine: in vivo microdialysis and motor behavior in rats. Brain Res 1992;579:87–92.
   PubMed Web of Science ®Google Scholar
• Rezvani AH, Overstreet DH, Lee YW. Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Pharmacol Biochem Behav 1995;52:615–620.
   PubMed Web of Science ®Google Scholar
• Maisonneuve IM, Keller RW Jr., Glick SD. Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. Eur J Pharmacol 1991;199:35–42.
   PubMed Web of Science ®Google Scholar
• Maisonneuve IM, Glick SD. Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine. Eur J Pharmacol 1999;383:15–21.
   PubMed Web of Science ®Google Scholar
• Maisonneuve IM, Mann GL, Deibel CR, Glick SD. Ibogaine and the dopaminergic response to nicotine. Psychopharmacology (Berl) 1997;129:249–256.
   PubMed Web of Science ®Google Scholar
• Glick SD, Maisonneuve IM, Visker KE, Fritz KA, Bandarage UK, Kuehne ME. 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Psychopharmacology (Berl) 1998;139:274–280.
   PubMed Web of Science ®Google Scholar
• Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, Bornmann WG, et al. Effect of iboga alkaloids on μ-opioid receptor-coupled G protein activation. PlosOne 2013;8:e77262.
   PubMed Web of Science ®Google Scholar
• Glick SD, Maisonneuve IM, Szumlinski KK. Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alkaloids Chem Biol 2001;56:39–53.
   PubMedGoogle Scholar
• Schneider JA, McArthur M. Potentiation action of ibogaine (bogadin TM) on morphine analgesia. Experientia 1956;12:323–324.
   PubMedGoogle Scholar
• Schneider JA. Assigned to Ciba Pharmaceutical Products Inc. Summit NJ. Tabernanthine, Ibogaine Containing Analgesic Compostions. US Patent no. 2,817,623. 1957.
   Google Scholar
• Bagal AA, Hough LB, Nalwalk JW, Glick SD. Modulation of morphine-induced antinociception by ibogaine and noribogaine. Brain Res 1996;741:258–262.
   PubMed Web of Science ®Google Scholar
• Cao YJ, Bhargava HN. Effects of ibogaine on the development of tolerance to antinociceptive action of mu-, delta- and kappa-opioid receptor agonists in mice. Brain Res 1997;752:250–254.
   PubMed Web of Science ®Google Scholar
• Bhargava HN, Cao YJ, Zhao GM. Effects of ibogaine and noribogaine on the antinociceptive action of mu-, delta- and kappa-opioid receptor agonists in mice. Brain Res 1997;752:234–238.
   PubMed Web of Science ®Google Scholar
• Sunder Sharma S, Bhargava HN. Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice. Pharmacology 1998;57:229–232.
   PubMed Web of Science ®Google Scholar
• Pearl SM, Johnson DW, Glick SD. Prior morphine exposure enhances ibogaine antagonism of morphine-induced locomotor stimulation. Psychopharmacology (Berl) 1995;121:470–475.
   PubMed Web of Science ®Google Scholar
• Skolnick P. Ibogaine as a glutamate antagonist: relevance to its putative antiaddictive properties. Alkaloids Chem Biol 2001;56:55–62.
   PubMedGoogle Scholar
• Trujillo KA, Akil H. Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists. Brain Res 1994;633:178–188.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Comer S, Ward A, Popik P, Kleber H, Fischman M. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl) 2001;157:1–10.
   PubMed Web of Science ®Google Scholar
• Panchal V, Taraschenko OD, Maisonneuve IM, Glick SD. Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. Eur J Pharmacol 2005;525:98–104.
   PubMed Web of Science ®Google Scholar
• Rho B, Glick SD. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats. Neuroreport 1998;9:1283–1285.
   PubMed Web of Science ®Google Scholar
• Deecher DC, Teitler M, Soderlund DM, Bornmann WG, Kuehne ME, Glick SD. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res 1992;571:242–247.
   PubMed Web of Science ®Google Scholar
• Sweetnam PM, Lancaster J, Snowman A, Collins JL, Perschke S, Bauer C, Ferkany J. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine’s putative anti-addictive activity. Psychopharmacology (Berl) 1995;118:369–376.
   PubMed Web of Science ®Google Scholar
• MacInnes N, Handley SL. Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine. Br J Pharmacol 2002;135:1227–1234.
   PubMed Web of Science ®Google Scholar
• He DY, McGough NNH, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, Janak PH, Ron D. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 2005;25:619–628.
   PubMed Web of Science ®Google Scholar
• Carnicella S, He DY, Yowell QV, Glick SD, Noribogaine RD. But not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. Addict Biol 2010;15:424–433.
   PubMed Web of Science ®Google Scholar
• Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW. Antagonism of α3β4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol 2002;438:99–105.
   PubMed Web of Science ®Google Scholar
• Pearl SM, Hough LB, Boyd DL, Glick SD. Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism. Pharmacol Biochem Behav 1997;57:809–815.
   PubMed Web of Science ®Google Scholar
• Baumann MH, Rothman RB, Pablo JP, Mash DC. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 2001;297:531–539.
   PubMed Web of Science ®Google Scholar
• Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol 2015;55:189–194.
   PubMed Web of Science ®Google Scholar
• Mash DC, Ameer B, Prou D, Howes JF, Maillet EL. Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. J Psychopharmacol 2016;30:688–697.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR); Washington. DC: American Psychiatric Association; 2000.
   Google Scholar
• Alper KR, Stajic M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci 2012;57:398–412.
   PubMed Web of Science ®Google Scholar
• Dickinson J, McAlpin J, Wilkins C, Fitzsimmons C, Guion P, Paterson T, Greene D, Chaves BR. Clinical guidelines for ibogaine-assisted detoxification, 1st edn., Version 1.1. Montreal, Quebec, Canada: Global Ibogaine Therapy Alliance (GITA); 2016. https://www.ibogainealliance.org/guidelines [accessed April 11, 2017].
   Google Scholar
• Cacciola JS, Alterman AI, McLellan AT, Lin Y-T, Lynch KG. Initial evidence for the reliability and validity of a “Lite” version of the Addiction Severity Index. Drug Alcohol Depend 2007;87:297–302.
   PubMed Web of Science ®Google Scholar
• Mcgahan PL, Griffith JA, Parente R, McLellan AT. Addiction severity index composite scores manual. Philadelphia, PA: The University of Pennsylvania/Veterans Administration Center for Studies of Addiction; 1986.
   Google Scholar
• Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating-scales for opiate withdrawal. Am. J. Drug Alcohol Abuse 1987;13:293–308.
   PubMed Web of Science ®Google Scholar
• Castelloe J. Equivalence WD and noninferiority testing using SAS/STAT® software. SAS Paper #1911-2015 2015, 1–23.
   Google Scholar
• Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 2006;145:62–69.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68:1238–1246.
   PubMed Web of Science ®Google Scholar
• Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat 2015;52:48–57.
   PubMed Web of Science ®Google Scholar
• Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2013;2:CD003409.
   PubMed Web of Science ®Google Scholar
• Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules 2015;20:2208–2228.
   PubMed Web of Science ®Google Scholar
• Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev 2010;62:760–781.
   PubMed Web of Science ®Google Scholar
• Alper K, Bai R, Liu N, Fowler SJ, Huang XP, Priori SG, Ruan Y. hERG blockade by iboga alkaloids. Cardiovasc Toxicol 2016;16:14–22.
   PubMed Web of Science ®Google Scholar
• Glick SD, Maisonneuve IM, Hough LB, Kuehne ME, Bandarage UK. (±)-18-Methoxycoronaridine: a novel iboga alkaloid congener having potential anti-addictive efficacy. CNS Drug Rev 1999;5:27–42.
   Google Scholar
• Alper KR, Lotsof HS. The use of ibogaine in the treatment of addictions. In: Winkelman M, Roberts T, eds. Psychedelic Medicine, Vol. 2. Westport, CT: Praeger/Greenwood Publishing Group; 2007:43–66.
   Google Scholar
• Fernandez JW. Bwiti: an ethnography of religious imagination in Africa; Princeton, New Jersey: Princeton University Press; 1982.
   Google Scholar
• Stolaroff M. The secret chief revealed. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies (MAPS); 2004.
   Google Scholar
• Naranjo C. The healing journey: new approaches to consciousness. New York: Pantheon, Random House; 1973.
   Google Scholar
• Fernandez JW, Fernandez RL. “Returning to the path”: the use of iboga[ine] in an equatorial African ritual context and the binding of time, space, and social relationships. Alkaloids Chem Biol 2001;56:235–247.
   PubMedGoogle Scholar
• Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998;51:253–263.
   PubMed Web of Science ®Google Scholar
• Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, Montoya I, et al. A Phase. 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend 2008;97:158–168.
   Google Scholar
• Smolka M, Schmidt LG. The influence of heroin dose and route of administration on the severity of the opiate withdrawal syndrome. Addiction 1999;94:1191–1198.
   PubMed Web of Science ®Google Scholar
• Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther 2014;348:217–226.
   PubMed Web of Science ®Google Scholar
• Farrell M. Opiate withdrawal. Addiction 1994;89:1471–1475.
   PubMed Web of Science ®Google Scholar
• Gerra G, Marcato A, Caccavari R, Fontanesi B, Delsignore R, Fertonani G, Avanzini P, et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995;12:35–41.
   PubMed Web of Science ®Google Scholar
• Loimer N, Linzmayer L, Grunberger J. Comparison between observer assessment and self rating of withdrawal distress during opiate detoxification. Drug Alcohol Depend 1991;28:265–268.
   PubMed Web of Science ®Google Scholar
• Gossop M. The detoxification of high-dose heroin-addicts in Pakistan. Drug Alcohol Depend 1989;24:143–150.
   PubMed Web of Science ®Google Scholar
• Gossop M, Griffiths P, Bradley B, Strang J. Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programs. Br J Psychiatry 1989;154:360–363.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. 2. Physiologic and behavioral-effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990;47:525–534.
   Google Scholar
• San L, Cami J, Fernandez T, Olle JM, Peri JM, Torrens M. Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. Br J Addict 1992;87:55–62.
   PubMedGoogle Scholar
• Alper KR, Beal D, Kaplan CD. A contemporary history of ibogaine in the United States and Europe. Alkaloids Chem Biol 2001;56:249–281.
   PubMedGoogle Scholar
• Drug Enforcement Administration (DEA). National Heroin Threat Assessment Summary - Updated. DEA-DCT-DIR-031-16; 2016
   Google Scholar
• Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev 2017; 2:Cd002025. doi:10.1002/14651858.CD002025.pub5
   Google Scholar
• Gowing L, Farrell M, Ali R, White JM. Alpha(2)-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2016;5: CD002024. doi:10.1002/14651858.CD002024.pub5
   Web of Science ®Google Scholar
• Welsch ME, Snyder SA, Stockwell BR. Privileged scaffolds for library design and drug discovery. Curr. Opin. Chem. Biol. 2010;14:347–361.
   PubMed Web of Science ®Google Scholar
• Szychowski J, Truchon JF, Bennani YL. Natural products in medicine: transformational outcome of synthetic chemistry. J. Med. Chem. 2014;57:9292–9308.
   PubMed Web of Science ®Google Scholar